News & Articles

Antigen test reliably and quickly triages people suspected of SARS-CoV-2, with results ready in 15 minutes, allowing informed treatment decisions

FoundationOne Liquid CDx analyzes more than 300 cancer-related genes and multiple genomic signatures to inform treatment decisions for all solid tumor cancers

Combining image analysis with structured reporting, the software aims to improve and accelerate the detection of the virus

Test delivers results in just 15 minutes with no instrumentation, using proven lateral flow technology with demonstrated sensitivity of 97.1% and specificity of 98.5%

The real-time PCR workflow has a capacity of up to 6,000 tests per day per system, and demonstrated 100% agreement with authorized nasopharyngeal assays

QIAseq SARS-CoV-2 Primer Panel converts viral RNA samples into libraries ready for sequencing, whereas QIAGEN Digital Insights solutions support COVID-19 drug, vaccine and epidemiology research

Syndromic testing will streamline respiratory infection diagnosis as COVID-19 pandemic collides with start of flu season

The AI-Rad Companion Brain MR and Prostate MR measures volumetric changes in brain, and segments prostate for targeted biopsy under MRI and ultrasound fusion imaging respectively

The Somatom scanner is equipped with a forward-looking camera and motorized wheels, allowing a single technologist to navigate the device through hospital hallways

Access Anti-SARS-CoV-2 is an easy-to-use 10-minute test on a portable device that provides highly accurate results on total Ig antibodies

The AccuPlex SARS-CoV-2 molecular controls kit is designed to measure day-to-day assay performance and contains positive materials

The test outperforms other molecular tests with a low detection limit of 15 GEC/reaction (250 GEC/ml of sample) and a robust control system

The consortium aims to determine the dynamics, function and potential for therapeutic intervention of the RNA and protein structures of SARS-CoV-2

IgM assay has 95.51% positive predictive value even when disease incidence is only 3%

The new assays are designed to enable turnaround times for next-generation sequencing results of less than 24 hours

Dr. Jeremy Hirota takes us through the technology behind his translational research program for respiratory health

Nirsevimab is the first potential passive immunisation for infants to demonstrate sustained protection across the entire RSV season with a single dose

In two clinical trials, Evrysdi improved motor function in people living with SMA over a broad spectrum of ages and levels of disease severity, including Types 1, 2, and 3 SMA

The high-throughput system enables laboratories to double or even triple their testing capacity

The partnership enables LUMICKS to expand on the implementation of the z-Movi to new immunotherapeutic settings

The new reagent kits aim to make whole genome sequencing more accessible and affordable for labs of all sizes

This powerful new solution aims to provide more accurate COVID-19 antibody detection

Join us on Tuesday, August 11, to learn about a novel serological platform used for COVID-19 testing

Join us on Monday, August 17, to discover solutions for your laboratory's SARS-CoV-2 testing